Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports?
about
Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer RiskHormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study populationPregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort.Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort studyRisk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapyEffect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.Concordance in histological and biological parameters between first and second primary breast cancers.Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences studyIntrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer StudyMortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 statusAsian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers.Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry.Estrogen-related genes and their contribution to racial differences in breast cancer risk.Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohortRacial and ethnic differences in adjuvant hormonal therapy use.Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium.Recreational physical activity and risk of triple negative breast cancer in the California Teachers StudyAlcohol consumption and breast cancer risk among postmenopausal women following the cessation of hormone therapy use: the California Teachers StudyIntratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis.Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry.Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.Breastfeeding Mode and Risk of Breast Cancer: A Dose-Response Meta-Analysis.Is the prevalence of ER-negative breast cancer in the US higher among Africa-born than US-born black women?Associations of sex steroid hormones with mortality in women with breast cancer.Tissue-based associations of mammographic breast density with breast stem cell markers.Short-term and long-term clinical outcomes of uncommon types of invasive breast cancers.Breast density influences tumor subtypes and tumor aggressiveness.Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study.Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study.Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype
P2860
Q31031200-4C1ECBBC-95ED-4DE5-BE66-EC620C6EF1A2Q31120324-968D7F80-6FB9-4A48-BDA8-FDA604DDFD6DQ33596695-AE93F445-8B99-4BEE-9E2C-B9A75C7968BBQ33729336-944EB4E7-7888-4DE3-B9FF-719E05F66900Q33919320-9687856B-E2D7-47EC-B67E-ECF647E95FF0Q34048111-4F615D1E-B86A-4883-8A84-B418C64C9E31Q34173479-CD5AF95C-331E-4195-94C9-DB742097D5FCQ34250220-48B124E3-803F-4A41-AECA-23C0018FF6ADQ34381496-8E898785-CB4A-4D3D-A4C5-1751133CD04AQ34500780-607300D6-10BD-4540-9849-34BAEE7B5B4CQ34514276-48723403-8679-4C2C-A755-8874A4F0E40BQ34530802-9E8C0107-0E87-4398-9CBF-5177836C18D8Q34705321-3DCCF4E6-FCD7-4C94-89F0-F24B2A87B3F9Q35146606-4B284843-DBDF-419F-8BBC-F338F2548DCCQ35170197-1A06B3CB-D58B-4944-AE67-B98CB748834EQ35220437-07BE6460-0E13-4C34-A73C-104EA39C9FFEQ35565644-9C754C4D-20FA-46CF-8006-011629F61017Q35750765-25786672-B7A8-433E-AC32-173B5C89723EQ35972488-B8689365-C62F-43F4-8DB3-1D8E81AB9789Q36004066-35ACEF32-AD4D-4DB0-AC94-A809E0E2E025Q36197983-85BC1985-C97D-455C-9566-EDB86A625F32Q36655887-422A3B9E-14CF-4D78-A723-6DBDA66A0FCCQ37018109-CD3AD315-ECFF-47DA-8112-A773A7605232Q37041238-AF53ADDA-C7C0-4B2C-9B63-7D8322171CBAQ37045365-1B31E314-E0E1-4C76-B9C1-C891F9113319Q37161492-48F4238B-D9A7-4EF9-8DA6-9DAAC730E6A4Q37586779-17E3E570-161E-4572-9E1A-CC4F3E779C6DQ37632099-53000F5C-C26E-4D3F-B506-FC70FF4D2814Q37690511-776142CE-882E-4BD4-AA90-851B79760A1EQ38377039-29D776AC-D7A2-419F-96FF-7CB7242EEFDCQ39135183-DD715457-BD0F-406D-9E70-4DA5681AA7A7Q39564960-1929958C-5709-4673-9455-4788316EDB57Q40006391-AFB7CAA4-17DE-421D-AB9A-9ACE3F80035BQ40066307-8378209A-B389-426D-8629-F78CF7D129DBQ40107400-45226A78-4BA6-4B5D-A7B7-21B85427C800Q42852622-AEB02506-DF02-4CE4-8F2F-BE3F8EBAD585Q47555930-CFA18076-5FA1-43A7-9EE6-AD3C3F506BB4Q48212165-58D2B84E-38ED-4525-B0DD-3C67E1238F1DQ48250088-AB6E5CDD-A6F9-4D1C-B507-70C539C514BEQ58769422-A651443F-96E8-40BD-A99D-3DCCA54E915A
P2860
Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Breast cancer receptor status: ...... ee with SEER registry reports?
@en
Breast cancer receptor status: ...... ee with SEER registry reports?
@nl
type
label
Breast cancer receptor status: ...... ee with SEER registry reports?
@en
Breast cancer receptor status: ...... ee with SEER registry reports?
@nl
prefLabel
Breast cancer receptor status: ...... ee with SEER registry reports?
@en
Breast cancer receptor status: ...... ee with SEER registry reports?
@nl
P2093
P2860
P50
P1476
Breast cancer receptor status: ...... ee with SEER registry reports?
@en
P2093
Brian L Strom
Jane Sullivan-Halley
Jill A McDonald
Kathleen E Malone
Linda Weiss
Michael F Press
Michael S Simon
Polly A Marchbanks
Robert Spirtas
P2860
P304
P356
10.1158/1055-9965.EPI-09-0301
P577
2009-08-01T00:00:00Z